Commercial-stage biopharmaceutical company Rhythm Pharmaceuticals Inc (Nasdaq:RYTM) announced on Wednesday that the European Commission has expanded the marketing authorisation for IMCIVREE (setmelanotide) to include children aged 2 to 6 years old.
IMCIVREE is indicated for patients with obesity due to Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency.
It is the first authorised precision medicine in the European Union for control of hunger and treatment of obesity in adults and children, now as young as 2 years old, living with these conditions.
BD receives FDA clearance for Surgiphor 1000mL irrigation system
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
FDA accepts rusfertide NDA and grants priority review for polycythemia vera
Innovent Biologics' Jaypirca approved in China for new indication
FDA accepts sNDA for MR-141 for the treatment of presbyopia
Lupin's Brivaracetam Oral Solution approved by US FDA
Johnson & Johnson submits sBLA to FDA for first-ever treatment for wAIHA
AlzeCure's ACD440 granted EU orphan drug status for erythromelalgia